Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 75 years (inclusive), of any gender
• People whose cancer cells test positive for a protein called CD123, confirmed by a laboratory blood test
• People with a confirmed diagnosis of CD123-positive AML (a type of blood cancer) or BPDCN (a rare blood cancer), where the disease has come back or has not responded to previous treatments — specific criteria apply to each condition separately (confirm with trial site)
• People expected to live for more than 12 weeks
• People who are reasonably physically active and able to care for themselves, as measured by a standard medical scoring tool called the ECOG scale (scores 0–2)
• People who do not have a severe mental health disorder
• People whose major organs are functioning at an acceptable level, including adequate blood cell counts, heart function, kidney function, liver function, and blood oxygen levels (specific thresholds apply — confirm with trial site)
• People, or their legal guardian, who are willing to sign a consent form confirming they understand and agree to take part in the trial

Who may not be able to join:

• People who have cancer that has spread to the central nervous system (brain and spinal cord) at the time of screening
• People who have received certain anti-cancer treatments, such as chemotherapy, targeted therapy, or experimental drugs, within 14 days or a specific time period before joining (unless their disease clearly progressed during that treatment)
• People who have had a stroke or epileptic seizure within the 6 months before screening
• People who have an active or uncontrolled infection requiring treatment within 1 week before screening
• People with certain serious heart conditions, including severe heart failure, a heart attack or major heart surgery within 6 months, significant irregular heartbeats, unexplained fainting episodes, or a history of severe heart muscle disease
• People who have an active autoimmune disease that requires long-term immune-suppressing medication
• People who have another current cancer, with some exceptions for certain treated skin cancers and other specific cancers that have been fully treated (confirm with trial site)
• People who have received a live vaccine within 4 weeks before screening
• People who are pregnant or breastfeeding, or people — male or female — who plan to have children within 1 year after receiving the trial treatment
• People the trial doctors consider unsuitable for the study for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.